Bumpus Namandje (CIK 2060594) reported 4 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-22). Recent activity: Buy RXRX (88,424 shares), Sell RXRX (3,963 shares), Buy RXRX (11,008 shares), Buy RXRX (36,549 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 88,424 | $0 |
| 2026-06-22 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Sell | 3,963 | $12,602 |
| 2025-06-23 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 11,008 | $0 |
| 2025-03-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 36,549 | $0 |
Source: SEC Form 4 filings · as of 2026-06-22